Cassava Sciences remains a high-risk, pre-revenue biotechnology firm entirely dependent on the successful clinical validation of its lead candidate, Simufilam. The company faces significant financial pressure as it navigates late-stage trials, evidenced by a c...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2025Latest Nov 12, 2025 | -$0.22+18.5% vs -$0.27 | — vs — |
Q3 2025 Aug 14, 2025 | -$0.18 vs — | — vs — |
Q2 2025 May 8, 2025 | -$0.48 vs — | — vs — |
Q2 2025 Mar 3, 2025 | -$0.57+16.2% vs -$0.68 | — vs — |
Benchmark SAVA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Cassava Sciences, Inc. (SAVA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.94 | $45.26M | -1.80 | — | — | -17.19% | — | |
| $25.43 | $4.35B | 11.10 | 11.87% | 33.42% | 32.39% | — | |
| $282.12 | $7.87B | -20.93 | -100% | — | -34.15% | — | |
| $1.18 | $37.02M | -1.08 | — | 32.23% | 83.42% | — | |
| $2.35 | $217.78M | -4.35 | — | — | -30.07% | — | |
| $2.83 | $288.02M | -3.34 | -86.92% | -246.49% | -99.17% | — |
Cassava Sciences, Inc. (SAVA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when SAVA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Cassava Sciences, Inc. (SAVA) stock FAQ — growth, dividends, profitability & financials explained
Cassava Sciences, Inc. (SAVA) reported a net loss of $106.0M for fiscal year 2024.
Cassava Sciences, Inc. (SAVA) has a return on equity (ROE) of -17.2%. Negative ROE indicates the company is unprofitable.
Cassava Sciences, Inc. (SAVA) had negative free cash flow of $83.9M in fiscal year 2024, likely due to heavy capital investments.
